These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 21750497)
21. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Straub N; Beivers A; Lenk E; Aradi D; Sibbing D Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566 [TBL] [Abstract][Full Text] [Related]
23. ADP receptor antagonism: what's in the pipeline? Angiolillo DJ Am J Cardiovasc Drugs; 2007; 7(6):423-32. PubMed ID: 18076209 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Teng R Clin Pharmacokinet; 2012 May; 51(5):305-18. PubMed ID: 22489610 [TBL] [Abstract][Full Text] [Related]
25. Randomized Comparison of Oral P2Y Hochholzer W; Kleiner P; Younas I; Valina CM; Löffelhardt N; Amann M; Bömicke T; Ferenc M; Hauschke D; Trenk D; Neumann FJ; Stratz C JACC Cardiovasc Interv; 2017 Jan; 10(2):121-129. PubMed ID: 28104204 [TBL] [Abstract][Full Text] [Related]
26. The P2Y12 receptor as a therapeutic target in cardiovascular disease. Storey RF Platelets; 2001 Jun; 12(4):197-209. PubMed ID: 11454254 [TBL] [Abstract][Full Text] [Related]
27. Optimizing antiplatelet therapy following percutaneous coronary intervention: clinical pathways for platelet function testing. Lassar TA; Simon DI; Croce K Rev Cardiovasc Med; 2011; 12 Suppl 1():S23-33. PubMed ID: 22080984 [TBL] [Abstract][Full Text] [Related]
28. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. Holmes LE; Gupta R; Rajendran S; Luu J; French JK; Juergens CP Cardiovasc Ther; 2016 Oct; 34(5):330-6. PubMed ID: 27327862 [TBL] [Abstract][Full Text] [Related]
29. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341 [TBL] [Abstract][Full Text] [Related]
30. Updates in antiplatelet agents used in cardiovascular diseases. Cheng JW J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):514-24. PubMed ID: 24213473 [TBL] [Abstract][Full Text] [Related]
31. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891 [TBL] [Abstract][Full Text] [Related]
32. Combined antiplatelet therapy: still a sweeping combination in cardiology. Manolis AS; Manolis TA; Papadimitriou P; Koulouris S; Melita H Cardiovasc Hematol Agents Med Chem; 2013 Jun; 11(2):136-67. PubMed ID: 23597106 [TBL] [Abstract][Full Text] [Related]
33. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Bernlochner I; Byrne RA; Kastrati A; Sibbing D Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045 [TBL] [Abstract][Full Text] [Related]
34. The use of platelet reactivity testing in patients on antiplatelet therapy for prediction of bleeding events after cardiac surgery. Leunissen TC; Janssen PW; Ten Berg JM; Moll FL; Korporaal SJ; de Borst GJ; Pasterkamp G; Urbanus RT Vascul Pharmacol; 2016 Feb; 77():19-27. PubMed ID: 26724555 [TBL] [Abstract][Full Text] [Related]
35. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104 [TBL] [Abstract][Full Text] [Related]
36. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E; Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851 [TBL] [Abstract][Full Text] [Related]
37. New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Sinhal AR; Aylward PE Clin Ther; 2013 Aug; 35(8):1064-8. PubMed ID: 23973039 [TBL] [Abstract][Full Text] [Related]